OneOncology Announces New Chairs for OneCouncil Disease Groups

This week, OneOncology announced the newly appointed chairs of the OneCouncil Disease Groups, who will serve for 2024 and 2025.

The 2024 and 2025 Disease Group chairs are:

Clinician Using Tablet Oncology Concept | image credit: WrightStudio - stock.adobe.com

Lung: Trevor Feinstein, MD, Piedmont Cancer Institute

Breast: Yelda Nouri, MD, New York Cancer & Blood Specialists

Gastrointestinal: Alfredo Torres, MD, New York Cancer & Blood Specialists

Genitourinary: Vasily Assikis, MD, Piedmont Cancer Institute

Hematologic Malignancies: Will Donnellan, MD, Tennessee Oncology

The OneCouncil Disease Groups offer a plethora of services across multiple areas including lung, breast, gastrointestinal, genitourinary, and hematologic malignancies. All physicians involved in this platform may receive and utilize disease-specific educational initiatives and subspecialized expertise.

The Disease Groups are additionally responsible for directing and approving OneOncology’s propriety pathways—many of which align with the evidence-based guidelines that are recognized nationwide. Upon presentation in peer-reviewed journal, or otherwise nationally recognized meetings, these pathways are reviewed and updated by The Disease Groups. Furthermore, they inform about noteworthy clinical trials to follow and strategies for innovative care, as well as guide topics on medical education and deliver Pharmacy & Therapeutics Committee expertise on recently approved therapies.

The outgoing chairs of the OneCouncil Disease Groups, who completed their 2-year terms, are: Henry Xiong, MD; Jahan Aghalar, MD; Greg Vidal, MD; Melissa Johnson, MD; and Jonathan Abbas, MD.

In a statement, OneOncology expressed deep gratitude and appreciation for the 5 outgoing chair members, their passion for bettering subspecialization in community oncology, and their dedication to each physician on the platform.

“Thank you to our outgoing Disease Group chairs for creating a strong culture of collaboration, and education, as well as for contributing their sub-specialization expertise to the creation of 25 pathways,” Davey Daniel, MD, OneOncology’s chief medical officer, said in the statement. “I look forward to working with our incoming chairs to continue to bring sub-specialization expertise to our platform.”